April 16, 2018 / 9:14 PM / 6 months ago

BRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors

April 16 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL-MYERS SQUIBB ANNOUNCES WORLDWIDE COLLABORATION WITH JANSSEN TO DEVELOP & COMMERCIALIZE BRISTOL-MYERS’ FACTOR XIA INHIBITOR, BMS-986177

* BRISTOL-MYERS SQUIBB SAYS JANSSEN WILL PAY CO UPFRONT SUM ALONG WITH POTENTIAL DEVELOPMENT & REGULATORY MILESTONE PAYMENTS

* BRISTOL-MYERS SQUIBB SAYS CO, JANSSEN EXPECTED TO ADVANCE BMS-986177 INTO PHASE 2 CLINICAL TRIALS IN H2 2018 FOR STUDY OF SECONDARY STROKE PREVENTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below